Maze Therapeutics, Inc.(MAZE)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,911 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
MAZE Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Maze Therapeutics, Inc. (MAZE), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MAZE at 10.3/100 on a 32-signal composite quality model, placing it at rank #2,911 of 2,962 stocks — the bottom half of the AI-ranked universe. MAZE scores in the top quartile across institutional flow (93.3). Areas of concern include revenue growth (1.0) and free cash flow (2.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 16.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Maze Therapeutics, Inc. reports net income of $-44.7M, free cash flow of $-15.2M. Top institutional holders of MAZE by reported 13-F value include Frazier Life Sciences Management, L.P., TRV GP IV, ARCH Venture Management, based on the most recent SEC filings. MAZE trades on the Nasdaq exchange and files with the SEC under CIK 1842295. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MAZE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Maze Therapeutics, Inc. directly from SEC EDGAR. Maze Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 10 and 29 since 2026, currently 10.3 — a declining long-term trajectory across 25 quarterly and live scoring snapshots.
Revenue
Q2 2026
$0.00
Net Income
Q2 2026
$-44.7M
Free Cash Flow
Q2 2026
$-15.2M
ROIC
Q2 2026
-39.1%
D/E Ratio
Q2 2026
0.09
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
-351.0% YoYOperating Income
-348.1% YoYEPS (Diluted)
-4494.8% YoYTotal Assets
+65.1% YoYOp. Cash Flow
-247.4% YoYFree Cash Flow
-250.7% YoY| Metric | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | — | $167.5M | — |
| Net Income | $-131.1M -351.0% | $52.2M | — |
| Operating Income | $-142.9M -348.1% | $57.6M | — |
| EPS (Diluted) | $-3.05 -4494.8% | $0.07 | — |
| Total Assets | $397.1M +65.1% | $240.5M | — |
| Operating Cash Flow | $-111.9M -247.4% | $76.0M | — |
| Free Cash Flow | $-112.7M -250.7% | $74.8M | — |
Get alerted when MAZE's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Maze Therapeutics, Inc. including:
Top Institutional Holders of MAZE
Frazier Life Sciences Management, L.P.
$150.2M5,032,915 shTRV GP IV, LLC
$133.5M4,473,958 shARCH Venture Management, LLC
$123.0M4,120,053 shDeep Track Capital, LP
$111.4M3,732,569 shBlackRock, Inc.
$104.5M3,502,841 shJupiter Topco LLC
$101.8M3,408,045 shT. Rowe Price Investment Management, Inc.
$77.7M2,603,682 shLogos Global Management LP
$57.7M1,935,000 shVANGUARD CAPITAL MANAGEMENT LLC
$53.1M1,778,222 sha16z Capital Management, L.L.C.
$50.8M1,702,225 sh
| Fund | Value | Shares |
|---|---|---|
| Frazier Life Sciences Management, L.P. | $150.2M | 5,032,915 |
| TRV GP IV, LLC | $133.5M | 4,473,958 |
| ARCH Venture Management, LLC | $123.0M | 4,120,053 |
| Deep Track Capital, LP | $111.4M | 3,732,569 |
| BlackRock, Inc. | $104.5M | 3,502,841 |
| Jupiter Topco LLC | $101.8M | 3,408,045 |
| T. Rowe Price Investment Management, Inc. | $77.7M | 2,603,682 |
| Logos Global Management LP | $57.7M | 1,935,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $53.1M | 1,778,222 |
| a16z Capital Management, L.L.C. | $50.8M | 1,702,225 |
Companies Similar to MAZE
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Relay Therapeutics, Inc.
MARAVAI LIFESCIENCES HOLDINGS, INC.
CytomX Therapeutics, Inc.
Celldex Therapeutics, Inc.
BioAge Labs, Inc.
Tango Therapeutics, Inc.
C4 Therapeutics, Inc.
NEKTAR THERAPEUTICS
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put MAZE on your watchlist
Track score changes the day Maze Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MAZE a good stock to buy?
13F Pro's AI-powered analysis of Maze Therapeutics, Inc. (MAZE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MAZE are available on the MAZE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MAZE is classified as a small company.
Which hedge funds own MAZE?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MAZE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Maze Therapeutics, Inc.'s investment landscape.